Hui Cai
Pfizer
7 Papers
10 Citations
Hui Cai is an academic researcher from Pfizer. The author has contributed to research in topics: Neutralization & Lineage (genetic). The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
Alexander Muik,Ann-Kathrin Wallisch,Bianca Sänger,Kena A. Swanson,Julia Mühl,Wei Chen,Hui Cai,Daniel Maurus,Ritu Sarkar,Özlem Türeci,Philip R. Dormitzer,Ugur Sahin +11 more
TL;DR: In this paper, the authors tested SARS-CoV-2-S pseudovirus bearing either the Wuhan reference strain or the B.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA-based COVID-19 vaccine BNT162b2.
543
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Jianying Liu,Yang Liu,Hongjie Xia,Jing Zou,Scott C. Weaver,Kena A. Swanson,Hui Cai,Mark Cutler,David A. Cooper,Alexander Muik,Kathrin U. Jansen,Ugur Sahin,Xuping Xie,Philip R. Dormitzer,Pei Yong Shi +14 more
TL;DR: The authors showed that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.
Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited sera
Pei Yong Shi,Jianying Liu,Yang Liu,Hongjie Xia,Jing Zou,Scott C. Weaver,Kena A. Swanson,Hui Cai,Mark Cutler,David K. C. Cooper,Alexander Muik,Kathrin U. Jansen,Ugur Sahin,Xuping Xie,Philip R. Dormitzer +14 more
- 21 May 2021
TL;DR: Twenty BNT162b2 vaccine-elicited human sera neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background and spike glycoproteins from the newly emerged B.1.617.1 and B. 1.525 variants to support mass immunization as a central strategy to end the COVID-19 pandemic across geographies.
BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants
Jianying Liu,Yang Liu,Hongjie Xia,Jing Zou,Scott C. Weaver,Kena A. Swanson,Hui Cai,Mark Cutler,David A. Cooper,Alexander Muik,Kathrin U. Jansen,Ugur Sahin,Xuping Xie,Philip R. Dormitzer,Pei Yong Shi +14 more
TL;DR: In this article, the authors report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 bearing variant spikes from Delta plus (Delta-AY.1, DeltaAY.2), Lambda, and B.1.519 lineage viruses.
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
Yang Liu,Jianying Liu,Hongjie Xia,Xianwen Zhang,Jing Zou,Camila R. Fontes-Garfias,Scott C. Weaver,Kena A. Swanson,Hui Cai,Ritu Sarkar,Wei Chen,Mark Cutler,David A. Cooper,Alexander Muik,Ugur Sahin,Kathrin U. Jansen,Xuping Xie,Philip R. Dormitzer,Pei Yong Shi +18 more
TL;DR: BNT162b2 Vaccine and Emerging SARS-CoV-2 Variants as mentioned in this paper showed strong neutralization activity against recombinant viruses in serum samples from 15 persons who received the BNT 162b2 vaccine.